Trial · NCT05019521
Participant flow56
How many started, completed or left each group, period by period.
1 to 20 of 56
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Primary Evaluation Period (52 Weeks) | STARTED | Danicopan 100 mg BID | 93 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Danicopan 200 mg BID | 91 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Danicopan 400 mg QD | 91 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Placebo | 90 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Placebo - Danicopan 100 mg BID | 0 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Placebo - Danicopan 200 mg BID | 0 | |
| Primary Evaluation Period (52 Weeks) | STARTED | Placebo - Danicopan 400 mg QD | 0 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Danicopan 100 mg BID | 93 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Danicopan 200 mg BID | 91 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Danicopan 400 mg QD | 91 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Placebo | 90 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Placebo - Danicopan 100 mg BID | 0 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Placebo - Danicopan 200 mg BID | 0 | |
| Primary Evaluation Period (52 Weeks) | Received at Least 1 Dose of Study Drug | Placebo - Danicopan 400 mg QD | 0 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Danicopan 100 mg BID | 73 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Danicopan 200 mg BID | 67 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Danicopan 400 mg QD | 73 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Placebo | 70 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Placebo - Danicopan 100 mg BID | 0 | |
| Primary Evaluation Period (52 Weeks) | COMPLETED | Placebo - Danicopan 200 mg BID | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05019521/flow